Is the so contemned reserpine back?
A review of the recent clinical assays that used reserpine at doses of 0.25 mg/day or less was made so as to determine whether these doses may be efficient and well tolerated. The causes leading to a decrease of its prescription, despite having considerably reduced the complications resulting from a...
Saved in:
Main Authors: | David García Barreto (Author), Alberto Toruncha Chukram (Author) |
---|---|
Format: | Book |
Published: |
ECIMED,
2014-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
¿Regresa la Tan vilipendiada reserpina?. Is the so contemned reserpine back?
by: David García Barreto, et al.
Published: (1998) -
Therapeutic potential of Reserpine in metabolic syndrome
by: Udaya Pratap Singh, et al.
Published: (2023) -
Effect of daidzein on Parkinson disease induced by reserpine in rats
by: Radha Goel, et al.
Published: (2020) -
Therapeutic potential of reserpine in metabolic syndrome: An evidence-based study
by: Kanika Verma, et al.
Published: (2023) -
Cannabidiol prevents motor and cognitive impairments induced by reserpine in rats
by: Fernanda Fiel Peres, et al.
Published: (2016)